Alex Leech

Alex Leech

Alex Leech was the founding CEO of Alchemab Therapeutics and raised a £60m ($82m) Series A in 2021. He is a serial biotech CEO having led Creabilis, a leading European dermatology company, until its acquisition by Sienna Biopharmaceuticals Inc. in December 2016 and...
John Kemp, PhD

John Kemp, PhD

John Kemp is currently the CSO of Syndesi Therapeutics. Former roles include Head of Neuroscience Discovery at Janssen, Belgium, and CEO of Evotec Neurosciences, which was spun-out from Evotec and raised a €25m Series A in 2004. Before joining Evotec, John was SVP and...
Preben Bruun-Nyzell

Preben Bruun-Nyzell

Preben is 2N Pharma’s co-founder and CEO and brings broad business and finance experience from an international career spanning nine countries over 25 years. He is co-founder of clinical-stage vaccine company 2A Pharma, and chairman...
John Nieland, PhD

John Nieland, PhD

John is 2N Pharma’s co-founder and CSO and brings broad management experience and in-depth research background. He was previously director of research at Medigene AG and is co-founder of the clinical-stage vaccine company 2A Pharma and two other biotech...
Giles Dudley, PhD

Giles Dudley, PhD

Giles Dudley is a Portfolio Manager at the BioInnovation Institute in Copenhagen and non-voting board observer. He has more than 10 years experience with fundraising, business development, market due diligence and IP development in biotech startups. Giles has a PhD in...